The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications
Abstract
The pathophysiological significance of hepatic lipid accumulation in the absence of significant alcohol consumption is increasingly recognised. Thus, non-alcoholic fatty liver disease (NAFLD) is now considered the most common cause of liver enzyme elevation in Western countries.1 It is regarded as the hepatic manifestation of the metabolic syndrome (MS), characterised by central obesity and insulin resistance (IR), and resulting diabetes type 2, dyslipidaemia and hypertension.2 NAFLD encompasses mild hepatic steatosis to steatohepatitis (non-alcoholic steatohepatitis (NASH)) with significant necroinflammation and progressive fibrosis. NAFLD is believed to account for a large fraction, if not entirely for what was previously termed ‘cryptogenic cirrhosis’.3 Since cirrhosis is the main risk factor for hepatocellular carcinoma (HCC), liver cancer could be simply a complication of end-stage NAFLD, similar to the situation encountered in other chronic fibrosing liver diseases. However, accumulating evidence suggests that hepatocarcinogenesis may also be related to earlier stages of NAFLD. Case series of patients with HCC and NAFLD as the only identified risk factor strongly suggest that hepatocarcinogenesis is part of the natural history of NAFLD. Based on the known association of NAFLD with IR and MS, approximately two-thirds of the patients were obese and/or diabetic,4 and a remarkable 25% of these patients had no cirrhosis. Considering the rapidly increasing prevalence of both conditions in affluent societies, and their significance in the pathophysiology of NAFLD, a rising incidence of NAFLD and its complications—including HCC—can be expected in the mid-term future. Therefore, it is particularly worrying that the most persuasive evidence for an association between NAFLD and HCC derives from studies on the risk of HCC in patients with MS. In a large prospective cohort study HCC mortality was significantly higher in obese subjects than in those with normal body mass index.5 The most comprehensive data underlining the significance …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“In a large prospective cohort study HCC mortality was significantly higher in obese subjects than in those with normal body mass index.(5) The most comprehensive data underlining the significance of diabetes as an important risk factors for HCC originate from a large Veteran Affairs study, which showed that the risk o…”
BackgroundGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 2×
“Interestingly, JNK and mTOR activity were increased in HFD-fed mice, and the activity of pro-oncogenic pathways as extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) was upregulated.(17) STAT3 is a major transcriptional target of interleukin 6 (IL-6) and its acti…”
BackgroundInsulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Hassan, M. M., Hwang, L.-Y., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002) · Hepatology · doi:10.1053/jhep.2002.36780 · Cited by 762
Kim, K. H., Shin, H., Kim, K., Choi, H. M., Rhee, S. H., Moon, H., Kim, H. H., Yang, U. S., Yu, D., & Cheong, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.039 · Cited by 281
Vinciguerra, M., Sgroi, A., Veyrat-Durebex, C., Rubbia-Brandt, L., Buhler, L. H., & Foti, M. (2009) · Hepatology · doi:10.1002/hep.22737 · Cited by 198
Cited by
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Self-citationChu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354
Metadata
- Authors
- Stickel, F., & Hellerbrand, C.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-07-21
- Volume
- 59
- Issue
- 10
- Pages
- 1303-1307
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2126374804
- Cited by
- 174
- References
- 8
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.